These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17630466)

  • 21. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs.
    Lim SS; Gaziano TA; Gakidou E; Reddy KS; Farzadfar F; Lozano R; Rodgers A
    Lancet; 2007 Dec; 370(9604):2054-62. PubMed ID: 18063025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Benefit-Cost Analysis of Select Secondary Prevention Interventions in LMIC.
    Nugent R; Brouwer E
    Glob Heart; 2015 Dec; 10(4):319-21. PubMed ID: 26704964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Nguyen E; Coleman CI; Nair S; Weeda ER
    J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opening the debate on DALYs (disability-adjusted life years).
    Barker C; Green A
    Health Policy Plan; 1996 Jun; 11(2):179-83. PubMed ID: 10172660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Societal costs of obstructive sleep apnoea syndrome.
    Gander P; Scott G; Mihaere K; Scott H
    N Z Med J; 2010 Aug; 123(1321):13-23. PubMed ID: 20927153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging epidemic of cardiovascular disease in developing countries.
    Reddy KS; Yusuf S
    Circulation; 1998 Feb; 97(6):596-601. PubMed ID: 9494031
    [No Abstract]   [Full Text] [Related]  

  • 27. Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases.
    Annemans L; Lamotte M; Clarys P; Van den Abeele E
    Eur J Cardiovasc Prev Rehabil; 2007 Dec; 14(6):815-24. PubMed ID: 18043305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interventions for the prevention of cardiovascular diseases: a protocol for a systematic review of economic evaluations in low-income and middle-income countries.
    Aminde LN; Veerman L
    BMJ Open; 2016 Dec; 6(12):e013668. PubMed ID: 28003298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based global cardiovascular disease control priority interventions.
    Huffman MD; Mohanan PP; Prabhakaran D
    Indian J Med Res; 2018 Sep; 148(3):247-250. PubMed ID: 30425212
    [No Abstract]   [Full Text] [Related]  

  • 30. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global burden of disease in young people aged 10-24 years: a systematic analysis.
    Gore FM; Bloem PJ; Patton GC; Ferguson J; Joseph V; Coffey C; Sawyer SM; Mathers CD
    Lancet; 2011 Jun; 377(9783):2093-102. PubMed ID: 21652063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global Patterns of QALY and DALY Use in Surgical Cost-Utility Analyses: A Systematic Review.
    Rios-Diaz AJ; Lam J; Ramos MS; Moscoso AV; Vaughn P; Zogg CK; Caterson EJ
    PLoS One; 2016; 11(2):e0148304. PubMed ID: 26862894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results.
    Toth PP; Stevens W; Chou JW
    J Med Econ; 2017 Jul; 20(7):749-751. PubMed ID: 28471246
    [No Abstract]   [Full Text] [Related]  

  • 35. Medical economics and the assessment of value in cardiovascular medicine: Part II.
    Mark DB; Hlatky MA
    Circulation; 2002 Jul; 106(5):626-30. PubMed ID: 12147547
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost and effectiveness of cardiovascular prevention.
    Boyar A
    Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
    [No Abstract]   [Full Text] [Related]  

  • 37. Health-related quality of life after stroke: review of the literature and implications for future research.
    Tseng MC; Lin HJ
    Acta Neurol Taiwan; 2007 Mar; 16(1):7-12. PubMed ID: 17486727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
    López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
    Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic burden of physical inactivity: healthcare costs associated with cardiovascular disease.
    Oldridge NB
    Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):130-9. PubMed ID: 18391637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The health gains and cost savings of dietary salt reduction interventions, with equity and age distributional aspects.
    Nghiem N; Blakely T; Cobiac LJ; Cleghorn CL; Wilson N
    BMC Public Health; 2016 May; 16():423. PubMed ID: 27216490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.